 Enrollment ongoing in Phase 1 dose-escalation trial BALLI-01 in rr B-ALL patients Enrollment ongoing in Phase 1 dose-escalation trial AMELI-01 in rr AML patients MELANI-01 trial in rr MM patients on hold; Cellectis is actively working with the FDA to safely resume the clinical development of UCART product candidate targeting CS1 in rr MM patients Enrollment ongoing in partnered programs1 utilizing Cellectis technologies: UCART19 PALL study in rr ALL pediatric patients, CALM study in rr ALL adult patients, ALLO-501 ALPHA study in rr NHL patients, ALLO-501A ALPHA2 study in rr NHL patients and ALLO-7152 UNIVERSAL study in rr MM patients Allogene Therapeutics and Servier presented data on the ALLO-501 partnered program at ASCO 2020, showing 44 CR and 75 ORR in CAR T-naïve rr NHL patients In-house US GMP Manufacturing Site in Raleigh, NC, on track to start production in 2021 Carrie Brownstein, M.D., appointed Chief Medical Officer, based in New York, NY Technical Operations to be led by Leopold Bertea, Ph.D., appointed SVP, Technical Operations Europe Steve Doares, Ph.D., appointed SVP, US Manufacturing and Site Head in Raleigh, NC Cash position3 of 317 million as of June 30, 2020NEW YORK, Aug. 05, 2020 GLOBE NEWSWIRE -- Cellectis Euronext Growth: ALCLS - Nasdaq: CLLS, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells UCART, today announced its results for the three-month and six-month periods ended June 30, 2020.Cellectis is 100 committed to finding cures for cancer patients. Enrollment is ongoing in two of our proprietary Phase 1 dose-escalation clinical trials; the BALLI-01 study, investigating UCART22 in patients with rr B-ALL, and the AMELI-01 study, investigating UCART123 in patients with rr acute myeloid leukemia AML. The MELANI-01 Phase 1 study, investigating UCARTCS1 in patients with rr MM, is presently on clinical hold and we are actively working with the U.S. Food and Drug Administration FDA to safely resume this study. I strongly believe our innovative UCART product candidates, including UCARTCS1, have great potential for cancer patients with unmet medical needs, and we will continue to safely develop these transformational product candidates, and adjust our studies, as needed, to effectively monitor and mitigate risks, said Dr. André Choulika, Chairman and CEO, Cellectis.In parallel to our clinical progress, I am extremely proud of the work that has been accomplished during the second quarter on our corporate side. Cellectis continued construction of its in-house GMP manufacturing facilities in Paris for UCART starting material and Raleigh for clinical and commercial UCART production, which remain on track for the anticipated start date for in-house production of our UCART product candidates in 2021. Additionally, we welcomed three industry leaders that add immense value to our team. Dr. Carrie Brownstein joined us as Chief Medical Officer, Dr. Leopold Bertea joined as Senior Vice President of Technical Operations Europe, and Dr. Steve Doares joined as Senior Vice President, US Manufacturing and Site Head in Raleigh, NC.1UCART19ALLO-501 is exclusively licensed to Les Laboratories Servier S.A.S. Servier, who has entered into a joint clinical development program with Allogene Therapeutics, Inc. Allogene Therapeutics. Servier is conducting the PALL and CALM and Allogene Therapeutics is conducting the ALPHA, ALPHA2 and UNIVERSAL studies pursuant to these arrangements.2UCARTBCMAALLO-715 is exclusively licensed to Allogene Therapeutics.3Cash position includes cash, cash equivalents and current financial assets and restricted cash. Restricted cash was 26 million as of June 30, 2020.Cellectis will hold a conference call for investors on Thursday, August 6, 2020 at 7:30 AM EDT 1:30 PM CET. The call will include the Companys second quarter results and an update on business activities.The live dial-in information for the conference call is: US Canada only: 1 877-407-3104International: 1 201-493-6792In addition, a replay of the call will be available until August 20, 2020 by calling 1 877-660-6853 Toll Free US Canada; 1 201-612-7415 Toll Free International.Conference ID: 13688263 Second Quarter 2020 and Recent HighlightsProprietary Allogeneic CAR T-Cell Development ProgramsAMELI-01 in rr AML patients and BALLI-01 in rr B-ALL patientsDuring the second quarter of 2020, both BALLI-01 and AMELI-01 continued to progress through dose escalation. As a reminder, BALLI-01 is planned to explore cohorts of patients at 3 dose levels, and AMELI-01 is planned to explore cohorts of patients at 4 dose levels. The primary objective of each first-in-human dose escalation study is to evaluate the safety of the respective product candidate and determine an optimal UCART dose and corresponding lymphodepletion regimen. In addition to safety, correlative studies will evaluate T-cell expansion, window of persistence and anti-tumor activity at all dose levels.Cellectis filed an amendment to the BALLI-01 trial with the FDA that adds an arm to the study in which patients will receive alemtuzumab in addition to fludarabine and cyclophosphamide in the lymphodepletion regimen. The optimal lymphodepletion regimen prior to the administration of CAR-T product candidates remains an area of investigation in the field of CAR T-cell therapy. As the inventor of the CD52 knockout, a concept and technology that are already incorporated in the current UCART123, UCART19, UCARTBCMA and UCART22 constructs, Cellectis will explore including alemtuzumab as part of the lymphodepletion regimen in a separate cohort of patients to guide the future development of UCART22 therapy in CD22 B-ALL.We plan to share preliminary data on one of our programs by the end of this year likely around the time of relevant scientific meetings.MELANI-01 clinical trial in rr MM patientsOn July 6, 2020, Cellectis announced that the MELANI-01 trial was placed on clinical hold by the FDA. This clinical hold, which impacts one of the three proprietary Cellectis product candidates currently in clinical studies, was initiated following the submission of a safety report regarding one patient with rr MM enrolled in the MELANI-01 study at dose level two DL2. This patient, who had been treated unsuccessfully with numerous lines of prior therapy including autologous CAR T-cells experienced a fatal treatment-emergent adverse event during the DLT period. Clinical evaluation of the case is ongoing, and additional details as to the immediate and underlying causes of this event are being investigated. Cellectis is working closely with the FDA, to address the agencys requests, which may include changes to the MELANI-01 clinical protocol that are designed to enhance patient safety. The requested information and amended protocol are expected to be submitted in due course.New AppointmentsIn April 2020, Carrie Brownstein, M.D., was appointed to the role of Chief Medical Officer. Dr. Brownstein oversees clinical research and development for Cellectis clinical programs. She is assuming her new position based in the Cellectis New York office and joined the Companys executive committee.Dr. Brownstein joined Cellectis as a seasoned clinical and medical expert from Celgene, where she most recently served as Vice President, Global Clinical Research and Development, Therapeutic Area Head for myeloid diseases. In this role, Dr. Brownstein managed a clinical team of physicians and scientists across multiple global sites and was responsible for management and cross-functional development of products to treat patients with myeloid diseases. Prior to her industry career, Dr. Brownstein practiced medicine as a pediatric oncologist within notable New York institutions such as New York Presbyterian Columbia University and Mount Sinai Medical Center.In May 2020, Leopold Bertea, Ph.D., was appointed to the role of Senior Vice President of Technical Operations Europe. He is responsible for ensuring execution across Technical Operations functions, including process development, analytical development, external supply, and the GMP Paris manufacturing facility that support the development and production of Cellectis proprietary product candidates.Dr. Bertea joined Cellectis as a recognized industry leader with over 25 years of experience in complex biotherapeutics, cell and gene therapies and combination products at several biopharmaceutical companies, including CellforCure, where he most recently served as General Manager and Site Head upon its acquisition by Novartis in April 2019. He successfully refocused the Les Ulis site from a multiproduct CDMO affiliate of LFB to the new European Novartis site dedicated to Kymriah autologous CAR-T cell and gene therapy production, as well as tech transfer and production of new cell and gene pipeline projects for Novartis. Dr. Bertea started his career with Novartis, where he became in charge of commercial monoclonal antibody production. Later, with Sanofi, he built up and led the first integrated Biologics CMC Platform, covering Sanofis biologics pipeline. Dr. Bertea then held the role of Vice President Bio-business Governance for Sanofis Global Biotherapeutics, managing the collaboration projects with partners. He was also a member of the Sanofi global RD Leading team and a senior Biologics Expert. Leopold Bertea holds a Ph.D. in Chemical Engineering from ETH Zürich.Steve Doares, Ph.D., joined Cellectis from Biogen in July 2020 as Senior Vice President, US Manufacturing and Site Head of the Raleigh, North Carolina manufacturing facility. Dr. 